9

Wakelin SJ, Mccole DC, Welsh F, Carden C, Auld ChD. ERCP: A single-centre study of 1020 cases. Acta Endoscopica 2008: 38(1):75-83. [More details]

8

Paikos D, Gatopoulou A, Moschos J, Soufleris K, Tarpagos A, Katsos I. Migrated biliary stent predisposing to fatal ERCP-related perforation of the duodenum. J Gastrointestin Liver Dis 2006; 15(4):387-8. [More details]

7

Testoni PA, Mariani A, Masci E, Curioni S. Frequency of post-ERCP pancreatitis in a single tertiary referral centre without and with routine prophylaxis with gabexate: a 6-year survey and cost-effectiveness analysis. Dig Liver Dis 2006; 38(8):588-95. [More details]

6

Disario JA. Hospital volume and ERCP outcomes: the writing is on the wall. Gastrointest Endosc 2006; 64(3):348-50. [More details]

5

Testoni PA. Facts and fiction in the pharmacologic prevention of post-ERCP pancreatitis: a never-ending story. Gastrointest Endosc 2006; 64(5):732-4. [More details]

4

Schmit A, Lazaraki G, Hittelet A, Cremer M, Le Moine O, Deviere J. Complications of endoscopic retrograde cholangiopancreatography during live endoscopy workshop demonstrations. Endoscopy 2005; 37(8):695-9. [More details]

3

Gottumukkala SR. Prevention of post-ERCP pancreatitis: are there any pearls for sale?. Gastroenterology 2004; 127(1):348-50. [More details]

2

Hilsden RJ, Romagnuolo J, May GR. Patterns of use of endoscopic retrograde cholangiopancreatography in a Canadian province. Can J Gastroenterol 2004; 18(10):619-24. [More details]

1

Testoni PA. Pharmacological Prevention of Post-ERCP Pancreatitis: The Facts and the Fiction. JOP. J Pancreas (Online) 2004; 5(4):171-8. [More details]